ReviewTranslational lung cancer research2026
Long-term survival and biomarkers of immunotherapy in small cell lung cancer: a systematic review.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Metastatic small cell lung cancer (SCLC) is a fast-progressing malignancy with a dismal prognosis. For many decades platinum-based chemotherapy (CT) has been the standard treatment, and recent clinical trials have demonstrated that the addition of immune-checkpoint inhibitors can improve the efficacy. However, for most of the patients the benefit is limited, as only a small percentage of them achieve long-term control of the neoplasm, and no predictive biomarkers have been characterized yet. Methods: We have conducted a systematic review in PubMed of articles studying long-term survival (LTS) in patients with advanced SCLC treated with immune checkpoint inhibitors (ICIs). Additionally, biomarkers predictive of efficacy of ICIs were also evaluated. Results: Forty-five articles were included out of 1,733 initially reviewed. Only four of them addressed LTS, although the definitions used were heterogeneous and no clear predictors were reported. Regarding predictive biomarkers of ICI efficacy, low tumor volume and the absence of systemic inflammation were associated with better outcomes. Conclusions: LTS is an unexplored rare phenomenon in SCLC, and further directed research is required to discover the mechanisms underlying this favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.